VOLUNTARY ANNOUNCEMENT FORMATION OF JOINT VENT

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”) is pleased to announce that CSPC NBP Pharmaceutical Co., Ltd.*(石藥集團恩必普藥業有限公司)(“NBP”, a wholly-owned subsidiary of the Company) and Shanghai Haihe Pharmaceutical Co., Ltd*(上海海和藥物研究開發有限公司)(“haihe”, an independent third party) established a joint venture, Shanghai Haishi Biopharmaceutical Co., Ltd.*(上海海石生物醫藥有限公司)(“Shanghai haishi”). Shanghai Haishi shall be principally engaged in the business of research and development (“r&d”) of innovative drugs. Its registered capital is RMB10,000,000 and its equity interest is owned as to 70% by NBP and 30% by Haihe.

READ DETAILS

ANNUAL REPORT 2018

For the year ended 31 December 2018, the Group achieved a revenue of HK$21,029 million, representing a 36.0% growth (or a 32.3% growth on a constant currency basis) year-on-year; and profit attributable to shareholders of HK$3,655 million, representing a 31.9% growth (or a 28.4% growth on a constant currency basis) year-on-year. Basic earnings per share amounted to HK58.55 cents (2017: HK45.48 cents).

READ DETAILS

NEW ORAL ANTI-COAGULANT DRUG “SYHA136” WAS GRANTED CLINICAL TRIAL APPROVA

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that “SYHA136” (the “Product”) developed by the Group was granted approval by the National Medical Products Administration to conduct clinical trials in China. The Product has a number of patent applications in China and overseas...

READ DETAILS

“PACLITAXEL CATIONIC LIPOSOME FOR INJECTION” FOR THE TREATMENT OF BREAST CANCER WAS GRANTED CLINICAL TRIAL APPROVAL

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that “paclitaxel cationic liposome for injection” developed by the Group (the “Product”) was granted approval by the National Medical Products Administration to conduct clinical trials in China...

READ DETAILS

VOLUNTARY ANNOUNCEMENT “SYHA1402” FOR THE TREATMENT OF DIABETIC NEUROPATHY WAS GRANTED CLINICAL TRIAL APPROVAL

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that “SYHA1402” (the “Product”) developed by the Group was granted approval by the National...

READ DETAILS

VOLUNTARY ANNOUNCEMENT “SYHA1803” FOR THE TREATMENT OF INTRAHEPATIC CHOLANGIOCARCINOMA AND UROTHELIAL CARCINOMA WAS GRANTED CLINIC

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that “SYHA1803” developed by the Group (the “Product”) was granted approval by the National...

READ DETAILS

ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2018

For the year ended 31 December 2018, the Group achieved a revenue of HK$21,029 million, representing a 36.0% growth (or a 32.3% growth on a constant currency basis) year-on-year; and profit attributable to shareholders of HK$3,655 million, representing...

READ DETAILS

VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NDA TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS

The board of directors (the “Board”) of the CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has successfully submitted a New Drug Application (NDA) to the U.S. Food ...

READ DETAILS

PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE

Reference is made to the announcements of the Company dated 27 December 2017 and 11 December 2018 (the “Announcements”) in relation to the Proposed A Share Listing of CSPC XNW on SZSE. Unless otherwise defined herein, capitalised terms used in this ...

READ DETAILS

VOLUNTARY ANNOUNCEMENT PRODUCT CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTS

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that Shanghai Runshi Pharma Technology...

READ DETAILS

ACQUISITION OF 100% INTEREST IN YONG SHUN TECHNOLOGY DEVELOPMENT LIMITED

On 4 January 2019, Dragon Merit, a wholly-owned subsidiary of the Company, entered into the Agreement with the Vendor pursuant to which Dragon Merit will acquire all the issued shares in Yong Shun on and subject to the terms and conditions of the...

READ DETAILS

PRODUCT CO-DEVELOPMENT AND STRATEGIC COLLABORATION AGREEMENT

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”) is pleased to announce that CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司) (“CSPC Ouyi”), a wholly-owned subsidiary of the Company...

READ DETAILS

PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”) is pleased to announce that CSPC Baike (Shandong) Biopharmaceutical Co, Ltd. (“CSPC Baike”), a wholly-owned subsidiary of the Company, has entered into an agreement (the “Agreement”) with I-Mab Biopharma (Shanghai) Co., Ltd. (“I-Mab”) in relation to the licensing and commercialization of...

READ DETAILS

THE group’S “Tirofiban Hydrochloride and Sodium Chloride Injection” WAS GRANTED DRUG REGISTRATION APPROVAL

The board of directors (the “Board”) of the CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the “Tirofiban Hydrochloride and Sodium Chloride Injection” (the “Product”) developed by the Group has been granted drug registration approval by the National Medical Products Administration of the People’s Republic of China...

READ DETAILS

the GrouP’S ProduCt CaNdidate “almB-0166” WaS GraNted orPhaN-druG deSiGNatioN BY the u.S. Fda

The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”,together with its subsidiaries, the “Group”) is pleased to announce that the Group’s product candidate “humanized connexin 43 monoclonal antibody (ALMB-0166)” was granted orphan-drug designation by the U.S. Food and Drug Administration (the “u.S. Fda”) for the treatment of acute spinal cord injury (“SCi”)....

READ DETAILS

QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2018

The Board of Directors of CSPC Pharmaceutical Group Limited (the “Company”) is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (the “Group”) for the nine months ended 30 September 2018 as follows...

READ DETAILS

2017 annual company report

For the year ended 31 December 2017, the Group recorded turnover of approximately HK$15,463 million, representing a 25.0% growth (or a 26.6% growth on a constant currency basis) year-on-year; and profit attributable to shareholders of approximately ...

READ DETAILS

六合宝典 六合宝典 六合在线 六合宝典 六合在线 六合宝典 六合在线 六合在线 六合在线 六合宝典